Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Current Liabilities (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Total Current Liabilities for 13 consecutive years, with $82.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 1.29% year-over-year to $82.2 million, compared with a TTM value of $82.2 million through Dec 2025, up 1.29%, and an annual FY2025 reading of $82.2 million, up 1.29% over the prior year.
  • Total Current Liabilities was $82.2 million for Q4 2025 at Agios Pharmaceuticals, up from $74.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $119.5 million in Q3 2024 and bottomed at $45.1 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $65.3 million, with a median of $60.2 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities crashed 52.55% in 2022, then soared 104.45% in 2024.
  • Year by year, Total Current Liabilities stood at $59.8 million in 2021, then grew by 4.69% to $62.6 million in 2022, then grew by 8.5% to $68.0 million in 2023, then grew by 19.43% to $81.2 million in 2024, then grew by 1.29% to $82.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for AGIO at $82.2 million in Q4 2025, $74.8 million in Q3 2025, and $70.4 million in Q2 2025.